Our pharmacogenomics engine leverages genomic sequences to capture the full genetic context driving drug response and safety risk. AI-driven de-centralized federated learning insights are validated by wet-lab biosensors, anchoring predictions in real biological evidence. At the patient level, our proprietary metrics — CIS, ESS, and DDH—enable precise patient stratification while unlocking new opportunities for drug repurposing, indication selection, and indication expansion. Together, this integrated approach surfaces safety and efficacy signals early, reducing late-stage failures and enabling truly personalized therapeutics.